WHAT RESEARCHERS MEASURED
What separate repair experiments reveal about KLOW peptide
KPV, GHK-Cu, BPC-157 and TB-500 experiments measured bowel damage, skin repair, and wounds. You can check which ingredient was tested and how far the findings reach.
The short answer about evidence for repair
Bowel damage, skin repair, tendon strength, and wound coverage changed in separate tests. Those measurements came largely from rodents and cells grown in the lab.
The ingredient studies concern KPV, GHK-Cu, BPC-157, and TB-500. The complete KLOW peptide mixture still lacks an animal or human comparison trial.
The ingredient, test subjects, and measured improvement belong together when you read a result, because a change in lab-grown cells answers a different question from healing in people. You can check those details against your own treatment question.
A treated rat recovering is a reason for further research. The rat didn't receive the whole mixture, so its improvement cannot establish what the mixture would do for your injury.
Much of the wound evidence tested the full protein behind TB-500. Those forms differ, and BPC-157's small human safety test didn't measure injury repair.
Published ingredient papers provide the numbers below and the limits beside them. The missing mixture comparison leaves both benefit and safety open.
KPV reduced damage in inflamed mouse bowels
A 2008 experiment found milder bowel disease in mice given KPV in water [3]. The water contained 100 micromolar KPV, a unit stating the amount dissolved in water.
That amount belongs to the mouse experiment, rather than your treatment. In separate lab experiments, researchers found less release of inflammation-causing substances from human bowel cells and also from immune cells.
A protein in inflamed bowel cells helps carry KPV inside. At about 160 micromolar, a measure of KPV in liquid, the protein carried KPV at half its fastest pace.
That finding measures how readily the cells take in KPV. The entry test doesn't measure bowel healing or establish an amount for you.
KPV is taken from a natural hormone's ending. The full hormone has a 13-residue chain, meaning linked protein parts.
In a 2003 experiment, researchers caused inflammation inside mice's bellies [9]. KPV appeared to quiet an inflammation-causing substance directly, unlike other pieces of the hormone.
KPV still worked when mice lacked a protein the parent hormone normally uses to affect cells. A 2008 bowel experiment also found less inflammation and earlier recovery of lost weight [10].
In 2017, mice swallowed KPV enclosed in tiny particles that reached the bowel [8]. A coating helped the particles attach to inflamed bowel cells, where KPV was needed.
Mice receiving those coated particles had less damage and inflammation than mice receiving particles without that coating. The comparison tested delivery to diseased tissue, rather than whether ordinary swallowed KPV helps people.
In 2024, researchers packed KPV with tacrolimus, a drug that slows the immune system [12]. The tiny particles entered inflamed bowel cells and carried both ingredients together.
The pair improved the bowel lining and reduced inflammation more than either alone. Mice benefited during both short bouts and lasting bowel inflammation.
No published human trial has tested KPV's effects throughout the body. Early work on skin treatment and bowel delivery hasn't established an approved KPV treatment.
GHK-Cu changed women’s skin and repair inside cells
A 2015 review by Pickart and Margolina described firmer, clearer skin after GHK-Cu treatment. Fine lines, wrinkle depth, and skin thickness also improved in the reviewed work.
The treatments went on the skin; researchers counted women making more collagen. That protein helps skin stay firm and gives other tissues strength.
With GHK-Cu, 70% of treated women made more collagen [4]. The share was 50% with vitamin C and 40% with retinoic acid, a skin treatment made from vitamin A.
Those percentages count women who improved, rather than the size of each improvement. The comparison also included a placebo, a dummy treatment for checking real benefit.
The skin results don't establish what injected GHK-Cu would do for you. In lab dishes, cells also increased production of materials used in repair, including collagen.
Blood fluid contains about 200 nanograms per milliliter of GHK-Cu at age 20. The amount falls to about 80 nanograms per milliliter at age 60 [4].
Nanograms measure billionths of a gram; milliliters measure liquid. Lower levels with age don't prove a benefit from extra GHK-Cu.
The usual vial contains approximately 50 mg of GHK-Cu in 80 mg total powder. Copper delivery therefore deserves attention alongside the repair findings.
In 2018, researchers examined protein-making genes, the instructions held in DNA [5]. They looked for a 50%-or-greater rise or fall in how much cells used each gene.
About 31% of the genes met that test for changed activity. Of those changed genes, 59% became more active and 41% less active.
The strongest changes involved tissue repair, DNA repair, cell protection, and waste removal. For waste removal, the counts were 41 busier genes and 1 quieter gene.
The counts describe cells using DNA instructions, rather than a healed injury. The repair changes suggest useful actions but don't establish an injection's benefit.
After GHK-Cu in a 2025 experiment, mice had less inflammation and damage in their bowels [13]. Their bowel lining recovered, helping keep bowel contents from leaking through the injured lining.
GHK-Cu supplies copper used to join collagen and other tissue proteins. If your body has trouble controlling copper, as in Wilson's disease, repeated delivery brings an unanswered safety question.
BPC-157 strengthened healing rat tendons; human safety evidence is small
Rats healed faster after researchers completely cut their Achilles tendons in a 2003 experiment [2]. Checks of strength, movement, and visible repair, with and without a microscope, established that improvement.
Different groups received 10 micrograms, 10 nanograms, or 10 picograms per rat. All amounts helped, and researchers gave the rats daily shots inside the belly.
These weights span millionths to trillionths of a gram. Separate tests on tendon cells grown outside animals found more outward growth.
BPC-157 also affects new blood vessels and control of blood flow [2]. Some effects remained when researchers used a substance to stop the body's usual production of a chemical that helps widen blood vessels.
The result suggests BPC-157 may affect blood flow through more than one route. That lab finding doesn't measure healing in your own tendon.
BPC-157 is made in the lab from part of a stomach-fluid protein. Its 15-amino-acid chain contains linked protein parts, and Body Protection Compound 157 is its longer name.
In a 2025 safety test, two healthy volunteers received vein drips of BPC-157 without a test of whether an injury healed [6]. A 58-year-old man and a 68-year-old woman took part.
The first day's amount was 10 mg on day 1; it rose to 20 mg on day 2. Each 1-hour drip used 250 milliliters of salt water, about a cup of liquid.
The researchers reported no harm in either volunteer during that small test. Tests of the liver, kidneys, heart, thyroid, and blood sugar stayed measurably unchanged.
Two people cannot establish how often harm might occur in others. The researchers also didn't test whether an injury healed.
An earlier FDA list put BPC-157 in category 2, a group raising safety concerns. That listing did not approve the ingredient as a medicine for people.
A 2025 review examined whether BPC-157 reduced harm after poisoning by other drugs or chemicals in animal experiments [14]. The review also discussed safety, rather than establishing a human treatment for poisoning.
A 2026 sports medicine review found encouraging animal repair results for BPC-157 and TB-500 [7]. Human safety evidence remained scarce, with possible serious harm and little drug oversight.
TB-500 differs from the protein that improved rat wounds
Deep rat wounds treated in 1999 grew more skin with thymosin beta-4. Compared with salt water, new skin coverage rose 42% at 4 days and up to 61% at 7 days.
Wounds also drew together at least 11% more by day 7. Both collagen and newly grown vessels increased in the tissue as wounds healed.
With as little as 10 picograms, a trillionth-of-a-gram unit, lab tests found a 2–3-fold rise in moving skin cells, meaning twice to three times as many cells moved [1]. The tests counted moving cells, rather than faster healing in people.
These results concern the full 43-amino-acid protein, whose chain contains linked protein parts. TB-500 contains a short portion of thymosin beta-4 made in the lab.
Much of the repair evidence therefore concerns a different form from TB-500. Your question about the shorter piece needs tests of the shorter ingredient itself.
A 2024 review described how thymosin beta-4 helps inflammation come to an end [11]. A 2025 experiment used a gel on wounds to carry the same full protein [15].
The protein sat inside tiny sacs released by cells and mixed into the gel. Wounds healed with a better blood supply after that treatment.
The sacs act as containers; the gel holds them at the wound. This was a wound treatment with the full protein, rather than a test of its injected short piece.
For cells moving across damaged skin, TB-500 holds a protein used in that movement. Full thymosin beta-4 has added actions that help cells move and bring repair cells toward the heart's surface.
Researchers haven't established those extra actions for the short TB-500 piece. Sharing part of thymosin beta-4 doesn't prove that both forms work alike.
Sports rules from WADA ban TB-500 and thymosin beta-4. KLOW effects explains what that means if your sport includes drug testing.
What a full mixture experiment still needs to measure
The full KLOW peptide mixture has no animal or human comparison trial. That means KPV, GHK-Cu, BPC-157, and TB-500 haven't been tested together against another treatment.
Researchers haven't compared the mixture with one ingredient or smaller mixtures. They also haven't used a placebo, a dummy treatment, to check the mixture's benefit.
No study measured all four ingredients moving through the body together. Your question about combined healing therefore lacks a direct result.
The smaller ingredients, KPV and GHK-Cu, clear faster than BPC-157. Their weights are 342–403 daltons, a tiny lab unit of weight that compares their sizes rather than treatment amounts.
TB-500 also has different times in the body from the full protein behind it. A mixed shot cannot keep each ingredient at an equal blood level, leaving your question about whether the ingredients help each other unanswered by these separate experiments.
A sports medicine review in 2026 judged animal repair findings encouraging, while finding little firm evidence of human safety and raising possible serious harm with unapproved ingredients including TB-500 and BPC-157 [7]. Your safety question remains open after that review.
Mixing those ingredients doesn't settle the concerns about each one. You still need evidence about both the individual ingredients and their combined effects.